Cargando…
Feasibility of a smartphone app to monitor patient reported outcomes in multiple sclerosis: The haMSter interventional trial
BACKGROUND: Monitoring of patient outcomes in multiple sclerosis (MS) is fundamental for individualized treatment decisions. So far, these decisions have been motivated by conventional outcomes, i.e., relapses or clinical disability supported by radiological disease activity. Complementing this conc...
Autores principales: | Altmann, Patrick, Ponleitner, Markus, Monschein, Tobias, Krajnc, Nik, Zulehner, Gudrun, Zrzavy, Tobias, Leutmezer, Fritz, Rommer, Paulus Stefan, Kornek, Barbara, Berger, Thomas, Bsteh, Gabriel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638697/ https://www.ncbi.nlm.nih.gov/pubmed/36353697 http://dx.doi.org/10.1177/20552076221135387 |
Ejemplares similares
-
The Smartphone App haMSter for Tracking Patient-Reported Outcomes in People With Multiple Sclerosis: Protocol for a Pilot Study
por: Altmann, Patrick, et al.
Publicado: (2021) -
Predisposing Factors for Sexual Dysfunction in Multiple Sclerosis
por: Altmann, Patrick, et al.
Publicado: (2021) -
Has the pandemic changed treatment strategy in multiple sclerosis?
por: Bsteh, Gabriel, et al.
Publicado: (2022) -
Correction: Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)
por: Monschein, Tobias, et al.
Publicado: (2023) -
Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)
por: Monschein, Tobias, et al.
Publicado: (2023)